| Placebo | Setipiprant 100 mg b.i.d. | Setipiprant 500 mg b.i.d. | Setipiprant 1000 mg b.i.d. | Setipiprant 1000 mg o.d. | Cetirizine 10 mg o.d. |
---|---|---|---|---|---|---|
Patients, n | 96 | 98 | 97 | 96 | 96 | 96 |
Age in years, mean (SD) | 42.2 (13.0) | 43.0 (12.1) | 42.0 (13.9) | 41.6 (11.7) | 41.8 (12.8) | 43.4 (12.8) |
Sex (% male: % female) | 28: 72 | 24: 77 | 32: 68 | 30: 70 | 35: 65 | 30: 70 |
Ethnicity, n (%): | ||||||
 Caucasian | 62 (65) | 56 (57) | 56 (58) | 58 (60) | 47 (49) | 51 (53) |
 Black | 3 (3) | 9 (9) | 9 (9) | 7 (7) | 7 (7) | 6 (6) |
 Hispanic | 31 (32) | 30 (31) | 32 (33) | 31 (32) | 41 (43) | 39 (41) |
 Other | – | 3 (3) | – | – | 1 (1) | – |
AR duration in years, mean (SD) | 18.8 (12.2) | 19.3 (11.4) | 19.1 (11.5) | 18.9 (12.3) | 19.8 (12.3) | 21.7 (16.8) |
Baseline DNSS, mean (SD)a | 2.25 (0.42) | 2.25 (0.40) | 2.26 (0.43) | 2.26 (0.41) | 2.24 (0.41) | 2.24 (0.42) |